OTCMKTS:CHSYF - China Medical System Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.20
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New China Medical System Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CHSYF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CHSYF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for China Medical System in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.20.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in China Medical System. This rating has held steady since January 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/21/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
(Data available from 4/18/2016 forward)
China Medical System logo
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products to hospital and medical institutions in the People's Republic of China. It offers products under the direct and agency networks. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for the treatment of blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise Tanshinone capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu, for treating respiratory diseases; Ganfule capsules for the treatment of primary carcinoma of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for bone pains; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. It also engages in the agriculture business. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
Read More

Today's Range

Now: $2.20
$2.20
$2.20

50 Day Range

MA: $1.75
$1.01
$2.40

52 Week Range

Now: $2.20
$1.01
$2.40

Volume

N/A

Average Volume

5,700 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of China Medical System?

The following Wall Street analysts have issued research reports on China Medical System in the last twelve months:
View the latest analyst ratings for CHSYF.

What is the current price target for China Medical System?

0 Wall Street analysts have set twelve-month price targets for China Medical System in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for China Medical System in the next year.
View the latest price targets for CHSYF.

What is the current consensus analyst rating for China Medical System?

China Medical System currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CHSYF.

How do I contact China Medical System's investor relations team?

The company's listed phone number is 86 755 8241 6868. The official website for China Medical System is www.cms.net.cn.